<DOC>
	<DOCNO>NCT02334488</DOCNO>
	<brief_summary>Prospective , multicenter , randomize open label study evaluate benefit renal function 12 month post-transplantation , immunosuppression without calcineurin inhibitor 3 month combine mycophenolate sodium-Everolimus versus immunosuppression combine Everolimus-Tacrolimus , de novo renal transplant patient .</brief_summary>
	<brief_title>Study Evaluating Benefit Two Immunosuppressive Strategies Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Patients receive first kidney transplant cadaveric living donor Double transplant Patient treat immunosuppressive drug study drug four week administration first dose Everolimus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>